Institute of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital, Erlangen, Germany.
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Am J Surg Pathol. 2020 May;44(5):703-710. doi: 10.1097/PAS.0000000000001428.
The molecular pathogenesis of poorly differentiated sinonasal carcinoma received significant attention in recent years. As a consequence, several unclassified carcinomas in the morphologic spectrum of sinonasal undifferentiated carcinoma have been reclassified as distinctive genetically defined variants or entities. Among the latter are NUT-rearranged carcinoma and SMARCB1-deficient carcinomas. In this study, we further characterize a rare variant of sinonasal undifferentiated carcinoma-like tumors characterized by inactivation of the SWItch/Sucrose Nonfermentable chromatin remodeler SMARCA4 (BRG1) detectable by immunohistochemistry. Patients were 7 males and 3 females aged 20 to 67 years (median, 44). Tumors originated in the nasal cavity (6), nose and sinuses (2), or at unspecified site (2). Six tumors were initially misdiagnosed as small cell neuroendocrine carcinoma (SCNEC) or large cell neuroendocrine carcinoma (LCNEC). Histologically, the tumors were composed of small basaloid (3 cases) or large epithelioid (7) cells disposed into nests and solid sheets with extensive areas of necrosis. No glands or other differentiating features were noted. Abortive rosettes were seen in 1 case. Immunohistochemistry showed consistent expression of pankeratin and absence of CK5, p63, p16, and NUT in all tumors tested. Other tested markers were variably positive: CK7 (2/6), synaptophysin (9/10; mostly focal and weak), chromogranin-A (4/10; focal), and CD56 (3/5; focal). All tumors showed total loss of SMARCA4 and retained expression of SMARCB1/INI1. Co-loss of SMARCA2 was seen in 1 of 8 cases. Limited data were available on treatment and follow-up. Two patients received surgery (1 also radiotherapy) and 3 received chemotherapy. Metastases (cervical nodes, liver, bone, and lung/mediastinal) were detected in 3 patients; 2 were alive under palliative chemotherapy at 8 and 9 months while 1 died of progressive lung disease at 7 months. Three patients (1 with brain invasion) died soon after diagnosis (1 to 3 mo). In total, 4 of 6 patients (66%) with follow-up died of disease (median, 3 mo). This series characterizes SMARCA4-deficient sinonasal carcinoma as a genetically distinct aggressive entity in the spectrum of undifferentiated sinonasal carcinomas. These variants add to the spectrum of SWItch/Sucrose Nonfermentable-deficient sinonasal carcinomas, at the same time expanding the topographic distribution of SMARCA4-related malignancies.
近年来,人们对低分化鼻窦癌的分子发病机制给予了极大关注。因此,鼻窦未分化癌形态谱中的一些未分类癌已被重新分类为具有独特遗传定义的变体或实体。后者包括 NUT 重排癌和 SMARCB1 缺陷型癌。在这项研究中,我们进一步描述了一种罕见的鼻窦未分化癌样肿瘤变体,其特征是免疫组化可检测到 SWItch/Sucrose Nonfermentable 染色质重塑酶 SMARCA4(BRG1)失活。患者为 6 男 3 女,年龄 20 至 67 岁(中位数,44 岁)。肿瘤起源于鼻腔(6 例)、鼻和鼻窦(2 例)或未指定部位(2 例)。6 例肿瘤最初误诊为小细胞神经内分泌癌(SCNEC)或大细胞神经内分泌癌(LCNEC)。组织学上,肿瘤由小的基底样细胞(3 例)或大的上皮样细胞(7 例)组成,呈巢状和实性片状排列,伴有广泛的坏死区。未见腺体或其他分化特征。1 例可见中断性菊形团。免疫组化显示所有检测的肿瘤均一致表达 pankeratin,而 CK5、p63、p16 和 NUT 均缺失。其他检测的标志物表达不同:CK7(2/6)、突触素(9/10;多为局灶性和弱阳性)、嗜铬粒蛋白 A(4/10;局灶性)和 CD56(3/5;局灶性)。所有肿瘤均显示 SMARCA4 完全缺失,SMARCB1/INI1 保留表达。8 例中有 1 例可见 SMARCA2 共缺失。治疗和随访的相关数据有限。2 例患者接受了手术(1 例还接受了放疗),3 例患者接受了化疗。3 例患者检测到颈部淋巴结、肝脏、骨骼和肺/纵隔转移;2 例患者在接受姑息性化疗后 8 个月和 9 个月时仍存活,1 例患者在 7 个月时死于进展性肺部疾病。3 例患者(1 例伴有脑侵犯)在诊断后不久死亡(1 至 3 个月)。总的来说,6 例有随访的患者中有 4 例(66%)死于疾病(中位时间为 3 个月)。该系列研究表明,SMARCA4 缺陷型鼻窦癌是一种在未分化鼻窦癌谱中具有独特遗传特征的侵袭性实体瘤。这些变体增加了 Switch/Sucrose Nonfermentable 缺陷型鼻窦癌的范围,同时扩大了 SMARCA4 相关恶性肿瘤的解剖分布。